Abstract 6109
Background
Brachytherapy unit of the Catalan Institute of Oncology (ICO) is a referral centre on Brachytherapy treatments for Catalonia. A total of 700 treatments are performed per year, mainly in gynaecological, prostate and breast cancer. For the last 5 years, intraoperative brachytherapy has been promoted to be done in other centres, outside in the region. That implies that specialist professionals from our cancer centre go to operating rooms in different hospitals. The surgery process is done outside in the Paediatric hospital and the Brachytherapy treatment is realised in the cancer centre ICO. Aim: to describe nursing activities and roles to facilitate the Brachytherapy treatment done outside and in collaboration with other hospitals.
Methods
Descriptive study on cases done last year 2018 with patients outside ICO, most common type of treatments were sarcoma in paediatric tumours, patients with recurrence disease undergoing salvage after surgery or recurrence for breast cancer. Procedure: When a case arrived to the specialist they confirm indication and initiate the process; On the day of surgery, a medical and nurses team from the brachytherapy unit moves to hospital They perform the placement of internal applicators at the time of surgery. Later next 12-24h patient moves to brachytherapy unit to undergo the protocol of radiation. Once the brachytherapy treatment is finished, patient is discharged. The nursing staff of brachytherapy unit takes charge of plan care during treatment.
Results
Pediatric brachytherapy in oncological patient: experience of collaboration of 5 years with 10 patients treated. A total of 53 breast brachytherapy has been done intraoperative: consolidated collaboration, generates around 3 monthly patients from different medical centers. A total of 10 cases done for salvage brachytherapy in patients with recurrence after surgery.
Conclusions
Intraoperative brachytherapy improves the patient’s accessibility to highly specialized treatments. The procedure and development of this treatment in different hospitals improves results in some tumours, reduces the overall time of treatment. Nursing staff has knowledge and skills for the management and care of this patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3349 - Interplay between miR-17-5p and MALAT-1 Shapes The Cytokine Storm in Triple Negative Breast Cancer (TNBC) Tumor Microenvironment
Presenter: Raghda Soliman
Session: Poster Display session 3
Resources:
Abstract
4014 - Clinical verification on the relationship between lipid metabolism and the immune microenvironment of breast cancer
Presenter: Wataru Goto
Session: Poster Display session 3
Resources:
Abstract
4158 - The clinical and transcriptional signatures of human CD204 reveal an applicable marker for tumor associated macrophage in breast cancer
Presenter: Yunjie He
Session: Poster Display session 3
Resources:
Abstract
5392 - Activated effector T cells co-expressing multiple inhibitory receptors (IRs) are enriched in the tumor immune microenvironment in high grade serous ovarian cancer (HGSOC)
Presenter: Alice Bergamini
Session: Poster Display session 3
Resources:
Abstract
2617 - Oncolytic reovirus as a new anti-tumor strategy in castration resistant prostate cancer
Presenter: Yunlim Kim
Session: Poster Display session 3
Resources:
Abstract
2995 - Dysregulation of helper T lymphocytes in esophageal squamous cell carcinoma (ESCC) patients is highly associated with aberrant production of miR-21
Presenter: Ali Memarian
Session: Poster Display session 3
Resources:
Abstract
3597 - Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma
Presenter: Christophe Borg
Session: Poster Display session 3
Resources:
Abstract
3430 - Evaluation of immune responses among responders (R) and non-responders (non-R) in a humanized mouse model with colorectal cancer (CRC) xenografts treated with combination immunotherapy
Presenter: Juan Marín Jiménez
Session: Poster Display session 3
Resources:
Abstract
1995 - ¬¬Advanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy
Presenter: Hansol Lee
Session: Poster Display session 3
Resources:
Abstract
3988 - Basal NK activity and early Treg function inhibition predicts Nivolumab responsiveness in metastatic renal cancer patients (REVOLUTION) trial.
Presenter: Sara Santagata
Session: Poster Display session 3
Resources:
Abstract